- Home
- RAND vs SYRS Comparison
RAND vs SYRS Comparison
Compare RAND & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- SYRS
- Stock Information
- Founded
- RAND 1969
- SYRS 2011
- Country
- RAND United States
- SYRS United States
- Employees
- RAND N/A
- SYRS N/A
- Industry
- RAND Finance: Consumer Services
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- SYRS Health Care
- Exchange
- RAND Nasdaq
- SYRS Nasdaq
- Market Cap
- RAND 47.5M
- SYRS 52.5M
- IPO Year
- RAND N/A
- SYRS 2016
- Fundamental
- Price
- RAND $17.13
- SYRS $1.94
- Analyst Decision
- RAND
- SYRS Strong Buy
- Analyst Count
- RAND 0
- SYRS 3
- Target Price
- RAND N/A
- SYRS $5.00
- AVG Volume (30 Days)
- RAND 2.3K
- SYRS 344.1K
- Earning Date
- RAND 11-04-2024
- SYRS 11-12-2024
- Dividend Yield
- RAND 6.99%
- SYRS N/A
- EPS Growth
- RAND 72.67
- SYRS N/A
- EPS
- RAND 4.19
- SYRS N/A
- Revenue
- RAND $7,874,601.00
- SYRS $4,149,000.00
- Revenue This Year
- RAND N/A
- SYRS N/A
- Revenue Next Year
- RAND N/A
- SYRS $614.29
- P/E Ratio
- RAND $4.06
- SYRS N/A
- Revenue Growth
- RAND 13.24
- SYRS N/A
- 52 Week Low
- RAND $12.50
- SYRS $1.43
- 52 Week High
- RAND $19.60
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- RAND 51.00
- SYRS 44.68
- Support Level
- RAND $16.46
- SYRS $1.93
- Resistance Level
- RAND $17.26
- SYRS $2.01
- Average True Range (ATR)
- RAND 0.35
- SYRS 0.12
- MACD
- RAND 0.06
- SYRS 0.06
- Stochastic Oscillator
- RAND 76.24
- SYRS 27.66
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.